New Work SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

New Work SE
New Work SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
12.01.2024 / 16:14 CET/CEST
Dissemination of a Voting Rights Announcement transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:New Work SE
Street:Am Strandkai 1
Postal code:20457
City:Hamburg
Germany
Legal Entity Identifier (LEI):5299002VHN50DM9T9H37

>
2. Reason for notification

XAcquisition/disposal of shares with voting rights
Acquisition/disposal of instruments
Change of breakdown of voting rights
Other reason:

>
3. Details of person subject to the notification obligation

Legal entity: Allianz Global Investors GmbH
City of registered office, country: Frankfurt/Main, Germany

>
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

>
5. Date on which threshold was crossed or reached:

11 Jan 2024

>
6. Total positions

% of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New2.95 %0.00 %2.95 %5620435
Previous notification3.02 %0.00 %3.02 %/

>
7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISINAbsoluteIn %
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE000NWRK01301655760.00 %2.95 %
Total1655762.95 %

>
b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrumentExpiration or maturity dateExercise or conversion periodVoting rights absoluteVoting rights in %
00.00 %
Total00.00 %

>
b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrumentExpiration or maturity dateExercise or conversion periodCash or physical settlementVoting rights absoluteVoting rights in %
00.00 %
Total00.00 %

>
8. Information in relation to the person subject to the notification obligation

Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
XFull chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

>

Name% of voting rights (if at least 3% or more)% of voting rights through instruments (if at least 5% or more)Total of both (if at least 5% or more)
-Allianz SE % % %
-Allianz Asset Management GmbH % % %
-Allianz Global Investors GmbH % % %

>
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rightsProportion of instrumentsTotal of both
% % %

>
10. Other explanatory remarks:

>
Date

12 Jan 2024

>

12.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com



Veröffentlicht am 12.01.2024

Aktuelle Research Artikel

Wasserstoff

Die nächste Evolutionsstufe der First Hydrogen Aktie

First Hydrogen Corp. Aktie (WKN: A3C40W): First Hydrogen Corp. zeigt mit über 630 km Reichweite und 1.500 Stopps in Tests, dass ihre Wasserstofftechnologie praxistauglich ist. Sie fokussieren nun auf Energieinfrastruktur.
Rohstoffe

Graphen verändert die Welt und die Argo Graphene Aktie ist ganz vorne dabei

Argo Graphene Solutions Corp. Aktie (WKN: A41C57): Argo Aktie interessant wegen Graphen, einem starken, dünnen und leitfähigen Material mit Potenzial in vielen Märkten.
Biotechnologie

Accum® als Plattform-Hebel: Signifikantes Kurspotenzial für die Defence-Aktie

Defence Therapeutics Inc. Aktie (WKN: A3CN14): Kanadisches Biotech-Unternehmen Defence Therapeutics steht vor der Herausforderung, seine Technologie in ein skalierbares Geschäftsmodell zu verwandeln.
Biotechnologie

Warum BioNxt jetzt in eine neue Bewertungsphase eintritt - mit Kurspotenzial von über 700 %

BioNxt Solutions Inc. Aktie (WKN: A3D1K3): BioNxt Solutions Inc. zeigt mit einer Studie, dass ihr Cladribin-ODF eine höhere Bioverfügbarkeit als Mavenclad® hat, was MS-Behandlung verbessern könnte.
 Ja, ich möchte den Newsletter abonnieren!*
* Sie können sich jederzeit aus dem Newsletter heraus abmelden. Weitere Informationen zum Thema Datenschutz erhalten Sie in unserer Datenschutzerklärung